APR 08, 2015 08:50 AM PDT

Possible New RNA Engineering Tool

Type III CRISPR-Cas complexes were shown to use a thumb-like domain (top right corner) to target specific sites on an RNA molecule for the destruction of invasive nucleic acids.Berkeley Researchers Report on CRISPR-Cas Surveillance Complex that Targets RNA.

A great deal of public attention in the past couple of years has been showered on complexes of bacterial proteins known as "CRISPR-Cas" for their potential use as a tool for editing DNA. Now, researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab) are reporting that CRISPR-Cas complexes could also serve as an engineering tool for RNA, the molecule that translates DNA's genetic instructions into the production of proteins.

Biochemist Jennifer Doudna and biophysicist Eva Nogales led a study that showed how a CRISPR-Cas surveillance complex in the bacterial immune system is able to target specific sites on an RNA molecule for the destruction of invaders. This targeting mechanism could be adapted by scientists for the genetic engineering of microbes to serve a plethora of purposes, including environmental clean-up, green chemistry, and the production of safer, more effective therapeutic drugs.

"We have provided the first high-resolution structural images of a fully intact Type III CRISPR-Cas surveillance complex and the first picture of how the RNA-targeting mechanism of this complex might work," says Nogales, a leading authority on electron microscopy.

"Our structural data suggests ways in which this RNA-targeting CRISPR-Cas complex could potentially be re-purposed for RNA-interference applications," says Doudna, a pioneer in the study and understanding of CRISPR-Cas complexes.

Both Doudna and Nogales hold joint appointments with Berkeley Lab, the University of California (UC) Berkeley, and the Howard Hughes Medical Institute (HHMI). They are the corresponding authors of a paper in Science that describes this research in detail. The paper is titled "Structures of the CRISPR-Cmr complex reveal mode of RNA target positioning." The lead author is David Taylor, a Damon Runyon Fellow and member of both the Doudna and Nogales research groups. Other co-authors are Yifan Zhu, Raymond Staals, Jack Kornfeld, Akeo Shinkai and John van der Oost

While we humans view bacteria as invading pathogens and have evolved an immune system for protection, bacteria themselves must confront a relentless tide of deadly invaders that include viruses and snippets of nucleic acid known as plasmids. To protect themselves, bacteria have evolved their own immune system. This system is adaptive and nucleic acid-based. It revolves around complexes featuring a genetic element known as CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, and an array of CRISPR-associated proteins collectively known as "Cas." Utilizing small customized CRISPR-derived RNA molecules (crRNA), CRISPR-Cas complexes identify and destroy the DNA of invading viruses and plasmids. There are three distinct types of CRISPR/Cas complexes. In this latest study, Doudna, Nogales and their colleagues focused on the Type III complexes, which recognize and cleave single-stranded RNA.

"Using near-atomic resolution cryo-electron microscopy reconstructions, we learned that Type-III CRISPR-Cas surveillance complexes employ a thumb-like domain intercalation between segments of targeted RNA to orient the RNA for productive cleavage," Taylor says. "Bacteria use this mechanism to destroy invasive nucleic acids from phages."

The thumb-like domains used by the Type-III CRISPR-Cas surveillance complexes share a "remarkable" architectural similarity to the thumb-like domains used by Type I CRISPR-Cas complexes for DNA targeting.

"This suggests a divergent evolution of these adaptive immune systems from a common ancestor," Taylor says. "Future structural and functional studies will be required to determine the atomic details of RNA cleavage that results from the Type-III CRISPR-Cas targeting system."

This research was primarily supported by the National Institutes of Health.

(Source: Lynn Yarris/newscenter.lbl.gov)
About the Author
You May Also Like
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
The Three Drugs that Reverse Biological Aging
In the last 100 years, life expectancy in the US has risen from 55 years until 79 (Roser: 2019). And with the continuous development of medicine and scie...
NOV 13, 2019
Immunology
NOV 13, 2019
Your Immune Response Varies from AM to PM
“My biological clock is ticking.” We’ve heard people say this phrase - maybe even said it ourselves - but what do we mean exactly? Often...
NOV 13, 2019
Immunology
NOV 13, 2019
Researchers Identify Pair of "Recruiters" that Pull T Cells to the Lungs
How do CD8 T cells make it to the lungs to help in the fight against infection? Why don’t T cells remain longer in the lungs? How can science optimiz...
NOV 13, 2019
Cancer
NOV 13, 2019
Unpacking lactate's role in the Warburg effect
In a recent issue of Nature, the findings of one study made a particularly big splash: how and why cancer cells use energy differently than healthy cells. ...
NOV 13, 2019
Microbiology
NOV 13, 2019
Measles Can Wipe Out the Memory of the Immune System
Researchers have learned how the measles vaccine can provide an additional layer of protection against more than just the measles....
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Promising Results for New Vaccine Against Dengue Fever
Dengue fever is an illness transmitted by mosquito bites. Affecting around 390 million people per year, if left untreated, its mortality rate is 20%. Altho...
Loading Comments...